Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28166
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPerret, Jennifer L-
dc.contributor.authorPlush, Brian-
dc.contributor.authorLachapelle, Philippe-
dc.contributor.authorHinks, Timothy S C-
dc.contributor.authorWalter, Clare-
dc.contributor.authorClarke, Philip-
dc.contributor.authorIrving, Louis-
dc.contributor.authorBrady, Pat-
dc.contributor.authorDharmage, Shyamali C-
dc.contributor.authorStewart, Alastair-
dc.date2017-03-30-
dc.date.accessioned2021-11-24T05:40:30Z-
dc.date.available2021-11-24T05:40:30Z-
dc.date.issued2017-05-
dc.identifier.citationRespirology 2017; 22(4): 662-670.en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/28166-
dc.description.abstractCoal workers' pneumoconiosis (CWP), as part of the spectrum of coal mine dust lung disease (CMDLD), is a preventable but incurable lung disease that can be complicated by respiratory failure and death. Recent increases in coal production from the financial incentive of economic growth lead to higher respirable coal and quartz dust levels, often associated with mechanization of longwall coal mining. In Australia, the observed increase in the number of new CWP diagnoses since the year 2000 has necessitated a review of recommended respirable dust exposure limits, where exposure limits and monitoring protocols should ideally be standardized. Evidence that considers the regulation of engineering dust controls in the mines is lacking even in high-income countries, despite this being the primary preventative measure. Also, it is a global public health priority for at-risk miners to be systemically screened to detect early changes of CWP and to include confirmed patients within a central registry; a task limited by financial constraints in less developed countries. Characteristic X-ray changes are usually categorized using the International Labour Office classification, although future evaluation by low-dose HRCT) chest scanning may allow for CWP detection and thus avoidance of further exposure, at an earlier stage. Preclinical animal and human organoid-based models are required to explore potential re-purposing of anti-fibrotic and related agents with potential efficacy. Epidemiological patterns and the assessment of molecular and genetic biomarkers may further enhance our capacity to identify susceptible individuals to the inhalation of coal dust in the modern era.en
dc.language.isoeng
dc.subjectcoal mine dust lung diseaseen
dc.subjectcoal miningen
dc.subjectcoal workers’ pneumoconiosisen
dc.subjecthealth surveillanceen
dc.subjectrespirable dusten
dc.titleCoal mine dust lung disease in the modern era.en
dc.typeJournal Articleen
dc.identifier.journaltitleRespirology (Carlton, Vic.)en
dc.identifier.affiliationInstitute for Breathing and Sleepen
dc.identifier.affiliationPM10 Laboratories Pty Limited, Somersby, New South Wales, Australiaen
dc.identifier.affiliationFaculty of Engineering and Informational Sciences, The University of Wollongong, Wollongong, New South Wales, Australiaen
dc.identifier.affiliationCentre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Pharmacology and Therapeutics, The University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationPump Investments Pty Limited, Melbourne, Victoria, Australiaen
dc.identifier.affiliationLung Health Research Centre (LHRC), The University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationAllergy and Lung Health Unit, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationFaculty of Medicine, Sir Henry Wellcome Laboratories, Southampton University Hospital, Southampton, UKen
dc.identifier.affiliationDepartment of Respiratory Medicine and Sleep Disorders, The Royal Melbourne Hospital, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment for Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationClinical and Experimental Sciences, University of Southampton, Southampton, UKen
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/28370783/en
dc.identifier.doi10.1111/resp.13034en
dc.type.contentTexten
dc.identifier.orcid0000-0001-7034-0615en
dc.identifier.orcid0000-0001-9290-1823en
dc.identifier.pubmedid28370783
local.name.researcherPerret, Jennifer L
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
crisitem.author.deptInstitute for Breathing and Sleep-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

8
checked on Nov 4, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.